Clinical trial
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
NCT00448149 · The Methodist Hospital Research Institute, Other · Completed
Key facts
| NCT number | NCT00448149 |
|---|---|
| Title | Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer |
| Official title | Phase I/II Trial of RAD001 Plus Nexavar® For Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | The Methodist Hospital Research Institute, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | RAD001, Sorafenib |
| Enrollment | 55 |
| Start date | Dec 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Mar 16, 2007 |
| Last update posted | Mar 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: